DAPA ACT HF-TIMI 68 is an investigator-initiated, randomized, double-blind, placebo-controlled trial in patients with heart failure who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin on the clinical outcomes of cardiovascular death or worsening heart failure.
MAIN RESULTS:
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure
Circulation. 2025 Nov 18;152(20):1411-1422.
PRIMARY RESULTS PRESENTATION
DAPA ACT HF-TIMI 68-Dapagliflozin in Patients Hospitalized for Acute Heart Failure (Berg, ESC 2025)
OTHER PRESENTATIONS
Blood Pressure and Symptomatic Hypotension with Dapagliflozin vs. Placebo in Patients Hospitalized with Heart Failure (Patel, AHA 2025)
DAPAgliflozin for TReatment of Inpatients and Outpatients with Heart Failure The DAPA-TRIO-HF Meta-Analysis (Berg, HFSA 2025)
Baseline Kidney Function and Safety and Efficacy of Dapagliflozin in Patients Hospitalized with Heart Failure (Patel, ACC 2026)
Safety and Efficacy of In-Hospital Initiation of Dapagliflozin with and without Concomitant Mineralocorticoid Receptor Antagonists-Findings from the DAPA ACT HF-TIMI 68 Trial (Monguillon, ACC 2026)
Dapagliflozin in patients hospitalized with newly diagnosed heart failure-A prespecified analysis of the DAPA ACT HF-TIMI 68 trial (Haller, ESCHF 2026)